Article
Multidisciplinary Sciences
Francisco J. Salguero, Andrew D. White, Gillian S. Slack, Susan A. Fotheringham, Kevin R. Bewley, Karen E. Gooch, Stephanie Longet, Holly E. Humphries, Robert J. Watson, Laura Hunter, Kathryn A. Ryan, Yper Hall, Laura Sibley, Charlotte Sarfas, Lauren Allen, Marilyn Aram, Emily Brunt, Phillip Brown, Karen R. Buttigieg, Breeze E. Cavell, Rebecca Cobb, Naomi S. Coombes, Alistair Darby, Owen Daykin-Pont, Michael J. Elmore, Isabel Garcia-Dorival, Konstantinos Gkolfinos, Kerry J. Godwin, Jade Gouriet, Rachel Halkerston, Debbie J. Harris, Thomas Hender, Catherine M. K. Ho, Chelsea L. Kennard, Daniel Knott, Stephanie Leung, Vanessa Lucas, Adam Mabbutt, Alexandra L. Morrison, Charlotte Nelson, Didier Ngabo, Jemma Paterson, Elizabeth J. Penn, Steve Pullan, Irene Taylor, Tom Tipton, Stephen Thomas, Julia A. Tree, Carrie Turner, Edith Vamos, Nadina Wand, Nathan R. Wiblin, Sue Charlton, Xiaofeng Dong, Bassam Hallis, Geoffrey Pearson, Emma L. Rayner, Andrew G. Nicholson, Simon G. Funnell, Julian A. Hiscox, Mike J. Dennis, Fergus Gleeson, Sally Sharpe, Miles W. Carroll
Summary: This study demonstrates that SARS-CoV-2 replicates in the upper and lower respiratory tract of both rhesus and cynomolgus macaques, causing pulmonary lesions. Immune responses against SARS-CoV-2 are similar in both species, suggesting that both macaque species authentically represent mild to moderate forms of COVID-19. The findings provide valuable insights for evaluating interventions against SARS-CoV-2.
NATURE COMMUNICATIONS
(2021)
Review
Pharmacology & Pharmacy
Xinyi Wang, Guozheng Tang, Yuchen Liu, Lizhi Zhang, Bangjie Chen, Yanxun Han, Ziyue Fu, Liuning Wang, Guangzhi Hu, Qing Ma, Shuyan Sheng, Jianpeng Wang, Xinyang Hu, Song Shao
Summary: SARS-CoV-2 infection can cause severe respiratory problems, including COVID-19 lung disease. IL-6 reduction in COVID-19 patients may have a previously undiscovered therapeutic impact, as IL-6 plays a key role in regulating inflammatory disorders. Therefore, IL-6 activation is important in the progression of coronavirus and is a rational therapeutic target for coronavirus inflammation.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Wilfredo F. Garcia-Beltran, Evan C. Lam, Michael G. Astudillo, Diane Yang, Tyler E. Miller, Jared Feldman, Blake M. Hauser, Timothy M. Caradonna, Kiera L. Clayton, Adam D. Nitido, Mandakolathur R. Murali, Galit Alter, Richelle C. Charles, Anand Dighe, John A. Branda, Jochen K. Lennerz, Daniel Lingwood, Aaron G. Schmidt, A. John Iafrate, Alejandro B. Balazs
Summary: Severe cases of COVID-19 show increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high antibody levels. High neutralization potency is a predictor of survival. Patient sera can neutralize different strains, indicating cross-protection from reinfection.
Article
Multidisciplinary Sciences
Salmaan Sharif, Aamer Ikram, Adnan Khurshid, Muhammad Salman, Nayab Mehmood, Yasir Arshad, Jamal Ahmed, Rana Muhammad Safdar, Lubna Rehman, Ghulam Mujtaba, Jaffar Hussain, Johar Ali, Mehar Angez, Muhammad Masroor Alam, Ribqa Akthar, Muhammad Wasif Malik, Mirza Zeeshan Iqbal Baig, Muhammad Suleman Rana, Muhammad Usman, Muhammad Qaisar Ali, Abdul Ahad, Nazish Badar, Massab Umair, Sana Tamim, Asiya Ashraf, Faheem Tahir, Nida Ali
Summary: The study found 27% of wastewater samples tested positive for SARs-CoV-2, indicating the potential for monitoring viral spread through wastewater surveillance. Additionally, the detection of virus sequence data in wastewater highlights the importance of surveillance for early warning signs.
Article
Microbiology
Claude Kwe Yinda, Julia R. Port, Trenton Bushmaker, Irene Offei Owusu, Jyothi N. Purushotham, Victoria A. Avanzato, Robert J. Fischer, Jonathan E. Schulz, Myndi G. Holbrook, Madison J. Hebner, Rebecca Rosenke, Tina Thomas, Andrea Marzi, Sonja M. Best, Emmie de Wit, Carl Shaia, Neeltje van Doremalen, Vincent J. Munster
Summary: The study demonstrates that humanized transgenic mice developed dose-dependent disease when inoculated with SARS-CoV-2, showing upper and lower respiratory tract infection with viral replication also in the brain. The pathological and immunological manifestations observed in these mice resemble human COVID-19, suggesting the model's usefulness in elucidating COVID-19 pathogenesis and testing countermeasures.
Review
Biochemistry & Molecular Biology
Qinrui Huang, Jiawei Zeng, Jinghua Yan
Summary: The ongoing COVID-19 pandemic has accelerated the development of mRNA vaccines, with positive results reported and future challenges ahead.
JOURNAL OF GENETICS AND GENOMICS
(2021)
Review
Microbiology
Jakob J. Malin, Isabelle Suarez, Vanessa Priesner, Gerd Fatkenheuer, Jan Rybniker
Summary: Remdesivir is the first approved treatment for COVID-19, showing therapeutic and prophylactic effects in animal models of various viruses. However, it failed in a clinical trial on ebolavirus disease but showed beneficial effects for patients with COVID-19 in a placebo-controlled trial.
CLINICAL MICROBIOLOGY REVIEWS
(2021)
Review
Medicine, General & Internal
Joseph V. Pergolizzi, Robert B. Raffa, Giustino Varrassi, Peter Magnusson, Jo Ann LeQuang, Antonella Paladini, Robert Taylor, Charles Wollmuth, Frank Breve, Maninder Chopra, Rohit Nalamasu, Paul J. Christo
Summary: Neurological manifestations are increasingly reported in a subset of COVID-19 patients, with growing evidence suggesting potential consequences particularly in severe cases. Patients with preexisting neurological conditions may be at elevated risk for COVID-19-associated neurological symptoms.
POSTGRADUATE MEDICINE
(2022)
Article
Virology
David A. Wells, Diego Cantoni, Martin Mayora-Neto, Cecilia Di Genova, Alexander Sampson, Matteo Ferrari, George Carnell, Angalee Nadesalingam, Peter Smith, Andrew Chan, Gianmarco Raddi, Javier Castillo-Olivares, Helen Baxendale, Nigel Temperton, Jonathan L. Heeney
Summary: This study investigates the cross-reactivity of antibodies between seasonal coronaviruses in humans and SARS-CoV-2, and their relationship with the severity of COVID-19. The findings suggest that although neutralizing antibodies against seasonal coronaviruses are common, there is little evidence that these antibodies can neutralize SARS-CoV-2.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Review
Chemistry, Multidisciplinary
Srinivasa Reddy Bonam, Niranjan G. Kotla, Raghvendra A. Bohara, Yury Rochev, Thomas J. Webster, Jagadeesh Bayry
Summary: COVID-19, caused by SARS-CoV-2, has become a global pandemic with significant mortality rates due to pulmonary pathology. Nanomedicine shows promise as a potential strategy in treating COVID-19.
Article
Multidisciplinary Sciences
Joshua G. Liang, Danmei Su, Tian-Zhang Song, Yilan Zeng, Weijin Huang, Jinhua Wu, Rong Xu, Peiwen Luo, Xiaofang Yang, Xiaodong Zhang, Shuangru Luo, Ying Liang, Xinglin Li, Jiaju Huang, Qiang Wang, Xueqin Huang, Qingsong Xu, Mei Luo, Anliang Huang, Dongxia Luo, Chenyan Zhao, Fan Yang, Jian-Bao Han, Yong-Tang Zheng, Peng Liang
Summary: Researchers have developed a trimeric vaccine candidate S-Trimer for COVID-19 based on Trimer-Tag technology. Immunization studies in animal models showed high levels of neutralizing antibodies and cellular immune responses, and protection from SARS-CoV-2 challenge in rhesus macaques. This technology may be crucial for scalable production of subunit vaccines against emerging RNA viruses.
NATURE COMMUNICATIONS
(2021)
Article
Green & Sustainable Science & Technology
Raghu Raman, Ricardo Vinuesa, Prema Nedungadi
Summary: India ranks fifth in COVID-19 research, along with the United States, China, the UK, and Italy. Most publications and citations from India are the result of collaborations with countries like the US, UK, China, and Saudi Arabia, primarily in the field of health sciences. India's involvement in COVID-19 research is increasing, with broader international collaborations.
Review
Medicine, Research & Experimental
Young Joo Han, Keum Hwa Lee, Sojung Yoon, Seoung Wan Nam, Seohyun Ryu, Dawon Seong, Jae Seok Kim, Jun Young Lee, Jae Won Yang, Jinhee Lee, Ai Koyanagi, Sung Hwi Hong, Elena Dragioti, Joaquim Radua, Lee Smith, Hans Oh, Ramy Abou Ghayda, Andreas Kronbichler, Maria Effenberger, Daniela Kresse, Sara Denicolo, Woosun Kang, Louis Jacob, Hanwul Shin, Jae Il Shin
Summary: This review conducted a systematic search to identify potential therapeutic agents for treating COVID-19 based on in vitro, in vivo, and clinical studies on SARS, MERS, and COVID-19. Results showed that there is no consistent therapeutic agent for the three diseases, but remdesivir demonstrated a therapeutic effect for COVID-19 in two randomized controlled trials with the largest number of participants. Further research and randomized controlled trials are needed to establish effective treatment strategies for COVID-19.
Review
Medicine, Research & Experimental
Aysan Moeinafshar, Niloufar Yazdanpanah, Nima Rezaei
Summary: COVID-19 is a viral disease caused by a coronavirus. The immune system plays a crucial role in the pathogenesis of COVID-19, making immune-based therapeutic approaches an interesting field of research.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Infectious Diseases
Mohamed Boudjelal, Faisal Almajed, Ahmed M. Salman, Naif K. Alharbi, Margaretta Colangelo, Julia M. Michelotti, Gene Olinger, Mariwan Baker, Adrian V. S. Hill, Ahmed Alaskar
Summary: The forum discussed the global challenges and prospects of COVID-19 vaccines, highlighting the importance of investing in biotech-pharma to combat future health crises, with a focus on Saudi Arabia's leadership in the field among G20 members.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)